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Abstract
HRAS is a proto-oncogene involved in the tumorigenesis of urinary bladder cancer. In the HRAS promoter we identified two
G-rich elements, hras-1 and hras-2, that fold, respectively, into an antiparallel and a parallel quadruplex (qhras-1, qhras-2).
When we introduced in sequence hras-1 or hras-2 two point mutations that block quadruplex formation, transcription
increased 5-fold, but when we stabilized the G-quadruplexes by guanidinium phthalocyanines, transcription decreased to
20% of control. By ChIP we found that sequence hras-1 is bound only by MAZ, while hras-2 is bound by MAZ and Sp1: two
transcription factors recognizing guanine boxes. We also discovered by EMSA that recombinant MAZ-GST binds to both
HRAS quadruplexes, while Sp1-GST only binds to qhras-1. The over-expression of MAZ and Sp1 synergistically activates HRAS
transcription, while silencing each gene by RNAi results in a strong down-regulation of transcription. All these data indicate
that the HRAS G-quadruplexes behave as transcription repressors. Finally, we designed decoy oligonucleotides mimicking
the HRAS quadruplexes, bearing (R)-1-O-[4-(1-Pyrenylethynyl) phenylmethyl] glycerol and LNA modifications to increase
their stability and nuclease resistance (G4-decoys). The G4-decoys repressed HRAS transcription and caused a strong
antiproliferative effect, mediated by apoptosis, in T24 bladder cancer cells where HRAS is mutated.
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Introduction
The ras gene family consists of three functional proto-oncogenes
(HRAS, NRAS and KRAS) that encode for guanine-binding proteins
sharing a high homology (p21RAS) [1]. These proteins, located on
the inner cell membrane through a farnesyl group [2], are active
when they are bound to GTP, and inactive when GTP is
hydrolyzed to GDP [3]. Ras proteins regulate cellular responses to
many extracellular stimuli, including mitogens and differentiation
factors [4]. The ras genes are expressed in a tissue-specific fashion:
HRAS is highly expressed in skin and skeletal muscles, KRAS in
colon and thymus and NRAS in male germinal tissue [1]. The ras
genes have similar structures and sequences with five exons, the
first of which is noncoding, and conserved splicing sites. The
introns, instead, have different lengths and sequences [1]. The ras
proto-oncogenes are converted to oncogenes by point mutations
that decrease the capacity of the encoded protein to hydrolyze
GTP to GDP, with the result that p21RAS remains constitutively
active. Hyperactivated ras proteins stimulate phosphorylation
cascades including the Raf/MEK/ERK pathway which leads to
uncontrolled cell proliferation [5,6]. Mutations in the ras genes are
frequently found in many human tumors [7,8]. HRAS mutations
are less common, but they have a high prevalence in skin
papillomas and urinary bladder tumors [9]. As 80% of bladder
tumors harbor HRAS mutations [10] and more than half of
bladder tumors overexpress HRAS [11], both mutation and
overexpression are important factors in the tumorigenesis of
bladder cancer [12]. Actually, it has been recently shown that low-
level expressions of constitutively active HRAS induced simple
urothelial hyperplasia, while the doubling of the activated HRAS
oncogene triggered rapidly growing and penetrating tumors
throughout the urinary tract. Given the crucial role of HRAS
overexpression and mutations in the tumorigenesis of bladder
cancer, one attractive therapeutic strategy could be to inhibit
HRAS transcription with molecules that are able to impair the
activity of the gene promoter. For this aim we asked how HRAS
transcription is regulated. We observed that the promoter of HRAS
contains numerous copies of the GGGCGGG element or its
complement. This G-box has been shown to interact with the Sp1
transcription factor [13,14]. Upstream of the transcription start
site (TSS) there are runs of guanines spanning over three Sp1 sites,
which are potential sites for G-quadruplex formation. We thus
hypothesized that the G-rich elements might play a role in
transcription regulation. G4-DNA are unusual structures stabilized
by planar arrays of four guanines (G-quartet) linked one to the
other by Hoogsteen hydrogen bonds [15]. The edges of the
terminal G-quartets are connected by loops that can vary both in
length and topology, giving rise to a variety of different
conformations [16]. Genome-wide analyses have revealed that
runs of guanines are abundant in gene promoter regions
surrounding TSS [17–20]. It has been theorized therefore that
G4-DNA might be involved in transcription regulation [21–25].
Our study provides compelling evidence that HRAS transcription
is regulated by the interplay between Sp1, MAZ and G4-DNA,
which acts as a transcription repressor. On the basis of this
discovery we have designed G-rich oligonucleotides specific for
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HRAS which have a strong antiproliferative effect in urinary
cancer cells bearing a mutant HRAS. Although the cytotoxicity of
certain G-rich oligonucleotides has been previously reported, their
mechanism of action is not yet fully understood [26,27]. Our study
shows that the designed quadruplex-forming oligonucleotides may
act by sequestering MAZ and thus impairing HRAS transcription.
For their potent antiproliferative effect in T24 urinary bladder
cancer cells, G4-decoys seem to be very promising effector drugs
for urinary bladder cancer therapy.
Results
The HRAS promoter is structurally polymorphic
The promoter of the human HRAS gene lacks typical TATA
and CAAT boxes, contains a high G+C content (80%) and
multiple copies of GGGCGGG (G-box), recognized by the
transcription factor Sp1 [13,14]. The three G-boxes closest to
the RNA start sites overlap quadruplex-forming sequences,
namely hras-1 (435–462, accession number J00277) and hras-2
(506–530, J00277) (Figure 1). According to a recent study,
quadruplex-forming sequences covering Sp1 binding elements
are present in several genes [28]. We have obtained a first hint that
the HRAS promoter is structurally polymorphic while sequencing
the expression vectors specially constructed for this study. When
sequencing primer-extension reactions were performed with
primers complementary to the G-rich strand, Taq polymerase
unexpectedly arrested at the hras-2 or hras-1 G-rich elements. In
contrast, with primers complementary to the C-rich strand we did
not observe any impediment. This suggested that both hras-1 and
hras-2 sequences formed unusual structures. Our hypothesis was
confirmed by polymerase-stop assays. We designed two linear
wild-type templates containing hras-1 or hras-2 and one mutant
template in which four GRT mutations were introduced into hras-
2 to prevent quadruplex formation. Primer-extension reactions
showed that Taq polymerase in the presence of potassium arrested
at the 39 end of hras-2 or hras-1, just before the first run of
guanines, in keeping with the formation of a G-quadruplex
structure by each G-rich element (Figure S1).
Promoter sequences hras-1 and hras-2 form stable G4-
DNA structures in vitro
An insight into the G-quadruplexes formed by the HRAS G-rich
elements was obtained by DMS-footprinting, circular dichroism
(CD) and fluorescence resonance energy transfer (FRET) exper-
iments. Figure 2 shows the results obtained with sequence hras-1.
The DMS-footprints of 27-mer hras-1 in water or buffer containing
100 mM Li+ or Cs+ (lanes 1, 4, 5) show that all guanines react with
DMS. Instead, in the presence of 50, 100 or 140 mM KCl (lanes
2, 3, 9), the guanines of the G-runs A–D are progressively
protected, while guanines G8 and G14 in the intervening
‘‘TTGC’’ and ‘‘CGCA’’ sequences are not. This cleavage pattern
suggests that hras-1 folds into a G-quadruplex (qhras-1). In the
presence of 50 nM TMPyP4, hras-1 gives a strong footprint either
at low (1 mM) or high (100 mM) KCl concentration (lanes 7, 8)
[29]. As expected, the mutant sequence h1-mut, bearing hras-1 with
four GRT mutations that abolish the folding, does not give any
footprint. To determine the strand orientation of qhras-1 we used
CD (Figure 2c,d). The CD spectrum of qhras-1 in 100 mM KCl is
characterized by positive and negative ellipticities at 287 and
260 nm, respectively, typical of an antiparallel conformation [30].
Heating the sample we obtained a melting curve (287 nm
ellipticity versus temperature) that was not perfectly superimposable
with the cooling curve, as the first was slightly biphasic while the
second was monophasic. A more sensitive method of analysis was
obtained by FRET-melting experiments with sequence hras-1 end-
labelled with FAM and TAMRA at the 5 and 39 end, respectively.
We obtained a well resolved biphasic melting curve with TM’s at
53 and 67uC indicating that hras-1 folds in at least two
quadruplexes (Figure 2e). When the concentration of hras-1 was
Figure 1. Sequence of the human HRAS promoter upstream of TSS. Two G-rich elements (hras-1 and hras-2) located upstream of
transcription start site can potentially fold into G-quadruplex structures. The quadruplex-forming G-rich elements contain the binding sites for the
transcription factors MAZ and Sp1.
doi:10.1371/journal.pone.0024421.g001
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increased one order of magnitude from 200 nM to 2 mM, the TM’s
did not change: a behavior typical of an intramolecular structure
(not shown). Together, these data suggest that hras-1 adopts an
antiparallel quadruplex which could assume different topologies:
the one with lateral loops is shown in Figure 2f [16]. Although we
know by footprinting and CD data the guanines that are involved
in the formation of antiparallel qhras-1, an insight into structure of
this quadruplex will only be obtained by NMR. Figure 3 shows the
results obtained with sequence hras-2. The DMS-footprints of 24-
mer hras-2 shows that in 10, 50, 100 and 140 mM KCl (lanes 2–5),
the G-runs A–D are protected from DMS, while G10, G12, G13,
G21 and G22 react with DMS. This indicates that the guanine
triads forming the quadruplex should be G3-G4-G5, G7-G8-G9,
G14-G15-G16, G18-G19-G20. The fact that G16 shows some
reactivity to DMS suggests that the pentaguanine G12-G16 stretch
can participate to the quadruplex either with G14-G15-G16 or
with G13-G14-G15. The mutant h2-mut sequence and wild type
hras-2 in 100 mM Li+ or Cs+ did not give any footprint (lanes 6–8).
The footprinting in the presence of 50 nM TMPyP4 is very strong
(lanes 9, 10). The CD spectrum of hras-2 shows a strong ellipticity
at 260 nm indicative of a G-quadruplex with a parallel
conformation (Figure 3c) [30]. This structure is so stable that the
CD at 85uC still shows an intense 260 nm ellipticity. The stability
at various KCl concentrations was determined with sequence hras-
2 labeled with FAM and TAMRA. We performed FRET-melting
experiments at 20, 40, 60, 100 and 140 mM KCl and obtained
TM values of 78 to 82, 85, .90 and .92uC, respectively
(Figure 3d). In this case, too, the TM’s did not change when the
concentration was increased one order of magnitude (from
200 nM to 2 mM) (not shown). Overall, our data demonstrate
that hras-2 forms a parallel G-quadruplex (qhras-2) whose putative
structure inferred by DMS-footprinting and CD should have
either 1/1/4 or 1/2/3 loops (Figure 3e). A definitive structure
assignment will only be possible on the basis of NMR data.
G4-DNA destabilizing point mutations in hras-1 and hras-
2 strongly upregulate HRAS transcription
As sequences hras-1 and hras-2 are located immediately upstream of
the transcription start site and form in vitro stable G-quadruplexes, we
asked what happens to HRAS transcription when the capacity of
quadruplex formation by sequences hras-1 and hras-2 is abolished. To
address this point we constructed a plasmid, pHRAS-luc, bearing
firefly luciferase driven by theHRAS promoter. From pHRAS-luc we
obtained by site-directed mutagenesis two mutant plasmids: pHRAS-
Figure 2. The G-rich element called hras-1 forms an antiparallel G-quadruplex structure. (a) Wild-type (hras-1) and mutated (h1-mut)
sequences analyzed by DMS-footprinting. Full squares indicate DMS-reactive guanines, open squares indicate DMS-unreactive guanines; (b) DMS-
footprinting of hras-1 in water (lane 1); hras-1 in 50 and 100 mM KCl (lanes 2 and 3); hras-1 in 100 mM CsCl or LiCl (lanes 4 and 5); h1-mut in 100 mM
KCl (lane 6); hras-1 in 50 mM TMPyP4, 1 mM KCl (lane 7); hras-1 in 50 mM TMPyP4, 100 mM KCl (lane 8); hras-1 in 140 mM KCl (lane 9); h1-mut in
100 mM KCl (lane 10); (c) CD spectra at 25 and 90uC show that hras-1 folds into an antiparallel G-quadruplex; (d) Melting curves for quadruplex hras-1
obtained plotting the 287-nm ellipticity against T. A TM of about 63uC was obtained by heating and cooling curves; (e) FRET-melting curves of
quadruplex hras-1 labelled with FAM and TAMRA show that it folds in two G-quadruplexes with TM of 53 and 67uC (Ex. 475 nm, Em. 520 nm); (f)
Possible conformations for hras-1, based on footprinting and CD data, are antiparallel quadruplexes with lateral and lateral/diagonal loops. The
quadruplex with lateral loops is shown in the figure.
doi:10.1371/journal.pone.0024421.g002
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mut1 and pHRAS-mut2, where two guanines in the second and third
G-tetrads of the putative quadruplexes were replaced with thymine/
cytosine or thymines (Figure 4a). These mutations abrogated the
capacity of sequences hras-1 and hras-2 to fold into a quadruplex
(Figure S2). The wild-type and mutant plasmids were co-transfected
in HeLa cells with pRL-CMV, a vector encoding for Renilla
luciferase. Forty-eight hours after transfection we measured firefly
and Renilla luciferases activity in the lysates of untreated and treated
cells. The results reported in Figure 4b show that blocking quadruplex
formation causes a dramatic increase of firefly luciferase expression,
up to 5-fold compared to control. This strongly indicates that the G-
quadruplexes formed by sequences hras-1 and hras-2 are structural
elements of the HRAS promoter that behave as repressors, as
observed for the CMYC gene [21].
G4-DNA stabilizing guanidinium phthalocyanines repress
HRAS transcription
Given that quadruplex DNA behaves as a repressor element for
HRAS, we examined the effect on transcription of G4-DNA
stabilizing ligands. Due to their specificity for G4-DNA, in our
experiments we used as ligands modified phthalocyanines: tetrakis-
(diisopropyl-guanidine) phthalocyanine (DIGP) and its Zn-containing
derivative Zn-DIGP (Figure 5a) [31–33]. HeLa cells were first treated
with 1 or 5 mMDIGP or Zn-DIGP for 24 h and then co-transfected
with a mixture of pHRAS-luc and pRL-CMV. After transfection, the
cells were let to grow for 48 h before firefly and Renilla luciferases
activity weremeasured with a luminometer. As a control (i) we treated
the cells with TMPyP2, a porphyrin that does not bind to G4-DNA
[34]; (ii) we used as a reporter vector pHRAS-mut1 or pHRAS-mut2
bearing a mutated G-element unable to form a quadruplex structure.
Figure 5b, c, d shows that DIGP and Zn-DIGP strongly inhibit
luciferase from wild-type pHRAS-luc, while TMPyP2 does not.
Moreover, the phthalocyanines do not inhibit luciferase in the cells
treated with the mutant plasmids pHRAS-mut1 or pHRAS-mut2, in
keeping with the fact that the G-quadruplexes cannot be formed by
these vectors. These data provide further evidence that quadruplexes
qhras-1 and qhras-2 act as transcription repressors.
Transcription factors Sp1 and MAZ bind to quadruplex
forming sequences (QFS) hras-1 and hras-2
As our transcription data suggest that both sequences hras-1 and
hras-2 are critical for transcription, we asked if they are recognized
Figure 3. Sequence hras-2 forms a parallel G-quadruplex structure. (a) wild-type and mutated hras-2 sequences analyzed by DMS-
footprinting. Full squares indicate DMS-reactive guanines, open squares indicate DMS-unreactive guanines; (b) DMS-footprinting of hras-2 in water
(lane 1); hras-2 in 1, 10, 50, 100 mM KCl (lanes 2–5); hras-2 in 100 mM LiCl or CsCl (lanes 6,7); h2-mut in 100 mM KCl (lane 8); hras-2 in 50 nM TMPyP4,
1 mM KCl (lane 9); hras-2 in 50 nM TMPyP4, 100 mM KCl (lane 10). Guanines G10, G12, G13 and G21, G22 are cleaved while the other guanines are not
(except G16 showing a low reactivity). Mutant h2-mut does not show any footprinting in 100 mM KCl; (c) CD spectra of quadruplex hras-2 at various
temperatures between 25 and 90uC suggest the formation of an antiparallel G-quadruplex; (d) FRET-melting of quadruplex hras-2 at 20, 40, 60, 100
and 140 mM KCl shows only one transition with TM of 78, 82, 85, .90, .92uC; (e) Possible G-quadruplex structure for hras-2, a parallel conformation
with 1/1/4 or 1/2/3 loops, based on footprinting and CD data.
doi:10.1371/journal.pone.0024421.g003
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by nuclear proteins. An answer to this question was obtained by
mobility-shift assays with a HeLa nuclear extract. Figure 6a shows
that both HRAS duplexes form with a HeLa nuclear extract
distinct DNA-protein complexes, thus pointing out the relevance
of these sequences for HRAS transcription. Ishii et al. showed that
sequence hras-2, which contains two copies of GGGCGGG, is
bound by Sp1 [13,14]. However, sequences hras-1 and hras-2
should also interact with the myc associated zinc-finger transcrip-
tion factor (MAZ), its binding site being (G/C)GG(C/A)GGG
[35,36]. In fact, it has been reported that MAZ and Sp1 often
regulate transcription in a cooperative way [37,38].
To prove that Sp1 and MAZ bind to sequences hras-1 and hras-2
under in vivo conditions, we performed chromatin immunoprecip-
itation (ChIP) experiments. Living HeLa cells were treated with
formaldehyde to crosslink the DNA-protein complexes, chromatin
was sheared into fragments and then immunoprecipitated with
anti-MAZ and anti-Sp1 antibodies (Abs). The abundance of HRAS
promoter sequences in the immunoprecipitates was measured by
PCR using primers specific for sequences hras-1 and hras-2. The
results reported in Figure 6b show that: IgG Ab did not
immunoprecipitate DNA-protein complexes containing sequence
hras-1 or hras-2 (negative control); anti-MAZ Ab did immunopre-
cipitate a DNA-protein complex containing hras-1 and hras-2; anti-
Sp1 Ab pulled down a complex with hras-2. By measuring the
intensity of the bands, we found that the HRAS sequences were
more abundant in the immunoprecipitates with anti-MAZ and
anti-Sp1 Abs than in the IgG Ab immunoprecipitate. We thus
concluded that under in vivo conditions MAZ is associated to
sequences hras-1 and hras-2, while Sp1 is associated to sequence
hras-2. This was confirmed by EMSA with recombinant MAZ and
Sp1 (Figure S3). As previous studies have shown that MAZ binds
to G4-DNA from the murine KRAS [24] and c-myb [39] promoters,
we explored whether it also binds to the HRAS quadruplexes. We
performed EMSA with recombinant MAZ and Sp1, which were
expressed in E. coli as GST fusion proteins (Figure S4). Figure 6c
shows that at pH 7.4, 50 mM KCl, qhras-1 and qhras-2 with
increasing amounts of MAZ-GST form - in the presence of 100-
fold excess nonradiolabelled poly d(I-C) - two retarded bands due
to the formation of two DNA-protein complexes, most likely with
1:1 and 1:2 stoichiometry. It is important to note that in 50 mM
CsCl, where the HRAS sequences are unstructured (see DMS
footprinting), both complexes are destabilized indicating that the
DNA-protein interaction is mediated by the quadruplex structure.
In a buffer at pH 9 where MAZ probably modifies its own folding,
the DNA-protein interaction is also inhibited. We also tested the
binding of Sp1-GST to the HRAS quadruplexes and found that
Sp1-GST interacts with the antiparallel qhras-1 quadruplex, but in
a weaker way compared to MAZ.
MAZ and Sp1 synergistically activate HRAS transcription
To prove that MAZ and Sp1 are involved in HRAS
transcription, we co-transfected plasmid pHRAS-luc in HeLa
cells either with pMAZ (encoding for MAZ) or pSp1 (encoding for
Sp1) or with a mixture of both plasmids (Figure 7a). When pMAZ
or pSp1 was cotransfected with the reporter vector, the level of
luciferase expression increased by 50% compared to control.
Figure 4. Effect of quadruplex DNA on HRAS transcription. (a) Two G4-DNA destabilizing point mutations in the hras-1 or hras-2 element have
been introduced. Plasmid pHRAS-mut1 contains a mutated hras-1 element, while plasmid pHRAS-mut2 contains a mutated hras-2 element; (b) Dual
luciferase assay showing that the point mutations cause up to a 5-fold increase in HRAS promoter activity (see Figure 5 legend).
doi:10.1371/journal.pone.0024421.g004
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When both pMAZ and pSp1 were cotransfected with the reporter
vector, transcription increased nearly 3-fold over control, indicat-
ing that both proteins synergistically activated HRAS promoter.
The synergy was stronger (7-fold compared to control) when
pMAZ and pSp1 were cotransfected with the mutant vector
pHRAS-mut1 or pHRAS-mut2, bearing mutated hras-1 or hras-2
sequences which are unable to form quadruplex structures. This
suggests that transcription is activated when sequences hras-1 and
hras-2 are in the unfolded duplex conformation. Furthermore, as a
proof that transcription requires both MAZ and Sp1, we knocked
down with validated shRNA each of the two transcription factors
separately (Figure S5). HeLa cells were treated with shRNA
specific for MAZ or Sp1 and the levels of HRAS transcripts were
measured by real-time PCR, at 48 and 72 h following treatment.
It can be seen that HRAS transcription was reduced to 30 and 20%
of control, 48 h following treatment with anti MAZ and anti Sp1
shRNA, respectively (Figure 7b). Taken together our data
demonstrate that HRAS transcription is activated synergistically
by MAZ and Sp1.
MAZ destabilizes the HRAS G-quadruplexes
Considering that MAZ is essential for HRAS transcription and
recognizes qhras-1 and qhras-2, we asked whether these quad-
ruplexes are unfolded by MAZ. To answer this question, we
performed FRET-melting experiments with recombinant MAZ-
GST. Quadruplex qhras-1 end-labelled with FAM and TAMRA
was incubated in 50 mM KCl, for 30 min in the presence of
increasing amounts of MAZ-GST or control protein (BSA or
trypsinogen). The melting curves (2dF/dT) showed that qhras-1
alone melts with its typical biphasic profile with TM at 53 and
67uC (Figure 8a curve 1). But when qhras-1 was incubated with
MAZ-GST at (moles of protein)/(moles of DNA) ratio r = 2.5, 5,
10 (curves 4, 5 and 6), the melting profile changed significantly as
the TM’s fell to ,46uC. This indicates that both qhras-1
quadruplexes are destabilized by MAZ-GST. As expected,
unspecific proteins such as BSA or trypsinogen at r = 10 did not
affect the melting of qhras-1 (curves 2,3). Due to its high stability in
potassium (TM=78uC in 10 mM KCl), qhras-2 was analyzed in
100 mM NaCl where the TM was 65uC. Incubated with MAZ-
Figure 5. Effect of quadruplex-stabilizing ligands on HRAS transcription. (a) Structure of tetrakis-(diisopropyl-guanidine) phthalocyanine
(DIGP) used, with its Zn-containing analogue Zn-DIGP, for luciferase experiments; (b) Dual luciferase assays showing that guanidinium
phthalocyanines DIGP and Zn-DIGP, stabilizing hras-1 and hras-2 quadruplexes, repress HRAS promoter activity. This effect is not observed with the
mutant plasmids pHRAS-mut1 and pHRAS-mut2 (control) (panels c and d). Relative luciferase is given by RT/RNT6100, where RT and RNT are (firefly
luciferase)/(Renilla luciferase) in T24 cells treated with phthalocyanines and untreated cells. Differences from the control are supported by Student’s t
test, P,0.05 (one asterisk), P,0.01 (two asterisks).
doi:10.1371/journal.pone.0024421.g005
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GST at r = 2.5, 5, 10, the quadruplex melted at 42uC, indicating
that also qhras-2 was destabilized by MAZ-GST, but not by BSA or
trypsinogen. We also ascertained that GST had no influence on
the melting of the HRAS quadruplexes (Figure S6b). An additional
control that we performed to rule out that bacterial proteins did
not contribute to quadruplex destabilization was to mix Glutathi-
one Sepharose 4B resin with an extract obtained from non-
transformed BL21 DE3 plysS bacteria. An SDS-PAGE analysis of
the eluate with 10 mM reduced glutathione showed that no
bacterial proteins bound non-specifically to the resin (Figure S6a).
We were surprised about the unfolding activity of MAZ, as we
recently reported that MAZ stabilized the murine KRAS quad-
ruplex [24]. However, it should be borne in mind that MAZ
having six zinc fingers can interact with DNA in a complex way, as
observed with qTBP42 and CBF-A [40,41]. These proteins disrupt
the dimeric quadruplex formed by the FMR1 d(CGG)n repeat but
they also stabilize the telomeric quadruplex d(TTAGGG)n. CBF-4
and qTBP42 have four RNP domains but only two are involved in
G4-DNA binding. It has been demonstrated that different RNP
combinations are responsible for either the stabilizing or the
destabilizing activity.
G4-DNA decoy ODNs mimicking HRAS quadruplexes
inhibit transcription and cell growth
Considering that HRAS transcription is activated by a combined
action of MAZ and Sp1 and that qhras-1 and qhras-2 bind to MAZ
(qhras-1 also binds to Sp1), we designed a decoy strategy against
HRAS oncogene. We reasoned that these oligonucleotides
mimicking quadruplexes qhras-1 or qhras-2 (G4-decoys) should
sequester MAZ and inhibit HRAS transcription as well as cell
growth (Figure 8c). To increase the stability of the G4-decoys we
inserted in their sequence one or two units of (R)-1-O-[4-(1-
Pyrenylethynyl) phenylmethyl] glycerol (P) to cap the quadruplex
ends [42]. To increase their resistance against endogenous
nucleases, we introduced LNA residues at the 39 end and in one
loop. We designed three G4-decoys mimicking quadruplex qhras-1
(3, 4 and 5) and three mimicking quadruplex qhras-2 (6, 7 and 8)
(Figure S7) (Table 2). The latter show CD spectra similar to that of
wild type qhras-2, with a strong ellipticity at 260 nm typical of a
parallel quadruplex conformation, while the former show a CD
slightly different from that of qhras-1, with two positive ellipticities
at 260 and 287 nm, suggesting that they should form a mixed
parallel-antiparallel quadruplex [43] (Figure 9a). The antiprolif-
erative activity of the designed G4-decoys was tested in two types
of cells: HeLa and T24 urinary bladder cancer cells that harbour a
mutant HRAS [codon 12 GGC (Gly) is changed in GTC (Val)],
expressing a hyperactivated HRAS protein [44]. In a first set of
experiments we delivered the G4-decoys (5 mM) without any
transfectant agent and did not observe any effect on cell
proliferation. To see if this was due to a poor oligonucleotide
uptake, we analyzed by confocal microscopy T24 bladder cells
treated for 24 h with 5 mM decoy 3 covalently labelled with
fluorescein (3-F). Figure 9b shows typical images: the nuclei
stained with propidium iodide (red fluorescence), the intracellular
Figure 6. Proteins MAZ and Sp1 interact with sequences hras-1 and hras-2. (a) EMSA showing the formation of DNA-protein complexes
between duplexes hras-1 and hras-2 and HeLa nuclear extract; amounts of extract used (mg) are indicated, radiolabelled DNA was about 4 nM. Letters
a, b and c indicate the DNA-protein complexes; (b) Chromatin immunoprecipitation analysis showing the interaction of MAZ and Sp1 with sequences
hras-1 and hras-2. The interaction between MAZ and Sp1 with the HRAS sequences was analyzed by a PCR amplification of 190 bp (hras-1) and
161 bp (hras-2) fragments. The two bands for complex MAZ:hras-1 have been obtained in the presence and absence of Mg2+ in the mixture (c) EMSA
showing the binding of MAZ-GST and Sp1-GST to quadruplexes qhras-1 and qhras-2.
doi:10.1371/journal.pone.0024421.g006
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distribution of the oligonucleotide (green fluorescence) and the
overlay of both emissions. It appears clear that 3-F localizes
basically in the cytoplasm, and this is the reason why the decoys are
not active when they are delivered as free molecules. We then
treated the cells with 3-F (350 nM) mixed to polyethylenimine
(PEI). Figure 9b shows that despite the low concentration, 3-F was
efficiently taken up by the cells and uniformly distributed in the
nucleus. We therefore decided to perform our proliferation
experiments using PEI as a transfectant agent. We did a dose-
response experiment by delivering the G4-decoys in two doses to
T24 cells, one 48 h after the other. Three days after the first
delivery, we performed a resazurin proliferation assay. It can be
seen that the three G4-decoys specific for hras-1 (3, 4 and 5)
promoted a dramatic inhibition of cell growth with IC50 of about
700 nM (Figure 9c). In contrast, only compound 6 specific for qhras-
2 showed some antiproliferative effect in T24 cells. Remarkably, the
oligonucleotides with the sequence of hras-1 (H1) or hras-2 (H2) and
control oligonucleotide 1450 (not folding into a quadruplex) did not
show any antiproliferative effect (H1 and H2 are probably degraded
by nucleases). A proliferation assay performed as a function of time
showed that the growth inhibition promoted by the G4-decoys did
not weaken over a period of 144 h (Figure S8).
Figure 7. MAZ and Sp1 sinergistically activate HRAS promoter. (a) HeLa cells transfected with pHRAS-luc/pRL-CMV, pHRAS-luc/pRL-CMV/
pMAZ; pHRAS-luc/pRL-CMV/pSp1; pHRAS-luc/pRL-CMV/pMAZ/pSp1. The dual luciferase assays were performed 24 h following transfection. Relative
luminiscence is given by RT/RNT6100, where RNT is (firefly luciferase)/(Renilla luciferase) in T24 cells treated with only pHRAS-luc and pRL-CMV, while
RT is (firefly luciferase)/(Renilla luciferase) in T24 cells treated with pHRAS-luc +pMAZ and/or pSp1+pRL-CMV. Differences from the control are
supported by Student’s t test, P,0.05 (one asterisk), P,0.01 (two asterisks); (b) Level of HRAS transcript in HeLa cells in which MAZ or Sp1 was
knocked down by validated shRNAs.
doi:10.1371/journal.pone.0024421.g007
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According to the postulated mechanism of action, the G4-
decoys 3, 4 and 5 should repress HRAS transcription by taking
MAZ (and Sp1) away from the promoter. Actually, we found that
the level of HRAS transcript, determined by real-time PCR 24 h
after decoy treatment, was reduced up to 30% of control, in T24
cells treated with the active decoys 3, 4 and 5 (specific for qhras-1).
In keeping with proliferation data, the decoys 7 and 8 that are not
active (specific for qhras-2) do not repress HRAS transcription
(Figure 10a). This result correlates with the finding that decoys 3, 4
and 5 strongly compete with the binding of MAZ to the hras-1
quadruplex, suggesting that these active decoys bind to MAZ
(Figure 10b).
Finally, an insight into the killing mechanism caused by the
designed G4-decoys was obtained by measuring the activity of
caspases 3 and 7 in untreated and decoy-treated T24 cells.
Figure 10c shows that decoys with the strongest antiproliferative
activity (3, 4 and 5) considerably activate caspases 3/7 (24 h after
treatment), suggesting that they promote cell death mediated by
apoptosis.
Discussion
The data of this study show that HRAS transcription is activated
by Sp1 and MAZ and repressed when the binding sites of these
proteins closest to TSS assume a folded G-quadruplex structure.
This is a new and compelling piece of evidence pointing to a
transcription mechanism which involves a simple on-off switch in a
gene regulatory region where unusual G-quadruplexes behave as
repressors. This was first proposed by Hurley and co-workers for
the CMYC gene [21]. Following this transcription model we
designed several decoy oligonucleotides in quadruplex conforma-
tion eliciting a potent antiproliferative effect in T24 urinary
bladder cancer cells bearing mutant HRAS.
ChIP assays showed that the G-rich elements called hras-1 and
hras-2, located upstream of TSS, are bound by the zinc-finger
proteins MAZ and Sp1. MAZ interacts with these promoter
sequences in a complex way, as it recognizes both duplex and
quadruplex conformations of hras-1 and hras-2. The binding to the
quadruplexes is catalytic in nature as qhras-1 and qhras-2 bound to
MAZ go through a destabilization process that decreases the
stability of the DNA-protein complexes (see EMSA). This means
that PAGE gives here only an apparent affinity between MAZ and
the HRAS quadruplexes, for which we estimated a KD of about
1.5 mM. One should also consider that by using recombinant
bacterially expressed proteins the binding data might be
underestimated, as recombinant proteins do not undergo the
post-translation modifications which occur in eukaryotic cells
necessary for optimal binding. For instance, MAZ shows optimal
binding to DNA when it is phosphorilated [45]. As a comparison,
it has been estimated by a filter binding assay that recombinant
Figure 8. MAZ destabilizes quadruplexes hras-1 and hras-2. FRET-melting experiment showing that in 50 mM KCl, MAZ-GST at r = 2.5, 5 and 10
(r = [MAZ]/[G4-DNA]) (curves 4, 5 and 6) destabilizes quadruplex qhras-1 in 50 mM KCl, 50 mM Zn-acetate [curve 1 (panel a)] and quadruplex qhras-2 in
100 mM NaCl, 50 mM Zn-acetate [curve 1, (panel b)]. BSA and TR (trypsinogen) at r = 10 do not have any effect on qhras-1 and qhras-2 quadruplexes)
(curves 2 and 3, panels a and b); (c) Schematic representation of HRAS transcription regulation proposed by this study. When the critical promoter
elements hras-1 and hras-2 are folded, they behave as transcription repressors. This is suggested by the fact that quadruplex-destabilizing point
mutations in hras-1 and hras-2 result in a significant increase of transcription, while quadruplex-stabilizing phthalocyanines are found to repress
transcription. MAZ, through its capacity to recognize the quadruplex structures, should be recruited to the promoter critical region. The MAZ-DNA
interaction destabilizes the G-quadruplexes, the critical hras-1 and hras-2 elements assume a duplex conformation that favors the binding of Sp1 and
other proteins of the transcription machinery. These events result in the activation of transcription.
doi:10.1371/journal.pone.0024421.g008
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nucleolin binds to parallel quadruplexes with a KD between 79 to
367 nM and it binds to mixed parallel antiparallel quadruplexes
with a KD of 0.45–2.5 mM [46]. Instead, by surface plasmon
resonance assay it has been found that recombinant nucleophos-
min binds to the CMYC quadruplex with a KD of 1.9 mM [47].
MAZ was identified as a G-box binding transcription factor for
CMYC [48]. Previous studies have shown that MAZ can either
activate [35–37,49–51] or repress [39,52] transcription. Further-
more, in certain genes MAZ regulates transcription together with
Sp1, as the two proteins can bind to the same guanine blocks: the
consensus sequence for MAZ is G(g/c)GGc/a GGGG(c/a)(g/t)
while that of Sp1 is (g/t)GGGCGG(g/a)(g/a)(c/t) [35]. When
MAZ or Sp1 was separately knocked-down with specific shRNAs,
HRAS transcription dropped respectively to 30% or 20% of
control. Conversely, when MAZ and Sp1 were over-expressed, a
synergistic effect was observed and HRAS transcription increased
3-fold compared to control.
To explore the role of G4-DNA on HRAS transcription we
introduced two quadruplex destabilizing GRT(C) point mutations
in sequences hras-1 or hras-2 and found that transcription increased
5-fold compared to control. A similar behavior was previously
reported for CMYC and CMYB genes [21,22,39]. Our conclusion is
that both HRAS G-quadruplexes behave as a molecular on-off
switch that either provides the binding sites to MAZ and Sp1 or
subtracts them. This is also supported by the fact that guanidinium
phthalocyanines stabilize the HRAS G-quadruplexes and repress
luciferase from pHRAS-luc to 20–30% of control, but not from
mutant vectors pHRAS-mut1 and pHRAS-mut2. In addition to
function as a transcription factor, MAZ is also able to remove the
structural blocking of transcription by the quadruplex structures,
as indicated by FRET-melting data.
In the light of all these findings, we designed G4-decoys
mimicking HRAS G-quadruplexes, which show a strong antipro-
liferative activity in T24 urinary bladder cancer cells harboring
mutant HRAS. We hypothesized that the G4-decoys should take
MAZ away from the promoter and inhibit HRAS transcription.
We found that in T24 bladder cells (but also in HeLa cells, not
shown) the decoys specific for quadruplex qhras-1 (3, 4, and 5)
displayed a dramatic inhibitory activity on cell growth, at a
concentration as low as 700 nM. Instead, only decoy 6 mimicking
quadruplex qhras-2 showed some activity. In keeping with previous
observations, our data suggest that quadruplex formation per se is
not sufficient to give rise to a bioactivity, as decoys 7 and 8 though
forming a stable quadruplex, are not active.
Figure 9. Effect on cell growth of G4-decoys. (a) CD of 2 mM G4-decoys 3, 4, 5, 6, 7, 8 in 100 mM KCl, 50 mM Tris-HCl, pH 7.4, cuvette 0.5 cm;
(b) confocal microscopy images of T24 cells treated with decoy 3 labelled with fluorescein in the presence and absence of polyethylenimmine (jet-
PEI). Top panel shows the nuclei stained with propidium iodide, mid panel shows the intracellular distribution of the decoy, bottom panel shows the
overlay; (c) Dose response assays in T24 urinary bladder cancer cells treated with the G4-decoys at increasing concentrations (100, 200, 300, 400, 600
and 800 nM - double delivery); differences from the control are supported by Student’s t test, P,0.05 (one asterisk), P,0.01 (two asterisks).
doi:10.1371/journal.pone.0024421.g009
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It is well known that certain G-rich oligonucleotides show a
clear antiproliferative effect in cancer cells which is not due to a
true antisense effect, but to their propensity to fold into a G-
quadruplex [26]. How these oligonucleotides precisely work, is not
yet clear, but Bates and co-workers proposed that the antiprolif-
erative activity of certain G-rich oligonucleotides requires:
nuclease resistance; efficient cellular uptake; binding to a specific
protein [53]. Our G4-decoys fulfill these requirements as: their
compact structure and LNA residues make them resistant to
nucleases; they efficiently penetrate cell membranes and internal-
ize in the nucleus when complexed with PEI; they interact with
MAZ, an essential protein for HRAS transcription.
That our G4-decoys act through their binding to a nuclear
protein (MAZ) is suggested by the fact that when they are
delivered without a transfectant agent, they localize in the
cytoplasm and are not active. In contrast, when they are delivered
with PEI, they reach the nucleus and show a strong antiprolifer-
ative activity.
In accord with the proposed mechanism of action, the decoys
eliciting the highest inhibition of cell growth (3, 4, 5) caused in
T24 cancer cells a strong decrease of HRAS transcript and
activation of caspases 3/7.
In summary, this work shows that: G4-DNA near the
transcription start sites of HRAS behaves as a transcription
repressor; MAZ and Sp1 bind to G-elements that can fold into
quadruplex forming sequences; transcription is activated by MAZ
and Sp1; MAZ destabilized the HRAS G-quadruplexes; G4-decoys
mimicking the HRAS quadruplexes behave as decoy molecules
against MAZ and cause a potent antiproliferative effect in T24
bladder cancer cells bearing mutant HRAS; the decoy strategy
could provide a new therapeutic approach to treat bladder cancer.
Materials and Methods
Plasmids and G4-decoys synthesis
pHRAS-luc was obtained by standard cloning, while mutant
plasmids pHRAS-mut1, pHRAS-mut2 were obtained by site
directed mutagenesis with the gene tailor kit (Invitrogen). A 838-
bp Sac I-Sac I fragment, obtained from pEJ 6.6 plasmid bearing
the human HRAS promoter, was cut with Xma I restriction
enzyme and the resulting 345 bp fragment was subcloned in
pGL3–E1 basic plasmid in Sac I-Xma I upstream of firefly
luciferase. In the resulting construct luciferase was driven by wild-
type HRAS promoter (pHRAS-luc). By site directed mutagenesis
we introduced in pHRAS-luc two point mutations either in hras-1
or hras-2 sequence. The primers used were 59- CGG GGC CGA
GGC CGG TGC GGT GCG TGT GCG TGT GC-39 (for) and
59-CCG GCC TCG GCC CCG GCC CTG GCC C-39 (rev).
Figure 10. Effect of G4-decoys on HRAS transcription. (a) Real-time PCR determination of the HRAS transcripts in T24 urinary bladder cancer
cells treated with 800 nM G4-decoys specific for hras-1 and hras-2 for 24 h; (b) EMSA showing that the DNA-protein complexes between 3 mg MAZ
and radiolabelled qhras-1 (10 nM) are competed away by cold G4-decoys 10- and 50-fold in excess compared to radiolabelled qhras-1 quadruplex; (c)
Caspase 3/7 assays showing that in T24 cells active G4-decoys 3, 4, 5 and 6 strongly activate apoptosis. Differences from the control are supported by
Student’s t test, P,0.05 (one asterisk), P,0.01 (two asterisks).
doi:10.1371/journal.pone.0024421.g010
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PCR was performed with 3 ng/ml DNA template, 0.1 mM each
primer, 0.05 units/ml AccuPrime pfx DNA polymerase (Invitro-
gen) in 16 AccuPrime pfx reaction mix for 3 min at 95uC, 30
cycles 1 min at 95uC, 30 s at 81uC, and 5 min at 68uC. Bacteria
DIH 101 5a were transformed with PCR product, and plasmid
DNA was extracted and sequenced (primer pGL3bpr 2 59-CTT
TAT GTT TTT GGC GTC TTC CA-39).
Plasmids pCMV-MAZ (called pMAZ), pCMV-Sp1 (called
pSp1), pGEX-MAZ and pGEX-Sp1 have been purchased by
RIKEN (Japan).
G4-decoys were synthesized on an ExpediteTM Nucleic Acid
Synthesis System Model 8909 from Applied Biosystems. Purifica-
tion of oligonucleotides was accomplished using a reverse-phase
semipreparative HPLC on Waters XterraTM MS C18 column.
Oligonucleotide concentrations were determined by UV-absor-
bance at 260 nm, 90uC and the calculated single-stranded
extinction coefficients were based on a nearest neighbour model
(extinction coefficient for monomers is 22400 at 260 nm).
CD and DMS footprinting experiments
CD spectra have been obtained with a JASCO J-600 spectro-
polarimeter equipped with a thermostatted cell holder, 3 mM
oligonucleotides in 50 mM Tris–HCl, pH 7.4, 100 mM KCl.
DMS footprinting experiments were performed using PAGE
purified oligonucleotides, 27-mer hras-1 and h1-mut, 24-mer hras-2
and h2-mut (20 nM), end-labelled with [c-32P]ATP (Perkin Elmer)
and polynucleotide kinase (New England Biolabs, MA). Before the
reactions they were incubated overnight at 37uC, in 50 mM sodium
cacodylate, pH 8, 1 mg sonicated salmon sperm DNA, 1 mM
EDTA, 100 mM KCl or LiCl or CsCl or KCl+TMPyP4 as
specified in figure legends. Dimethylsulphate (DMS) dissolved in
ethanol (DMS:ethanol, 4/1, vol/vol) was added to the DNA
solution (1 ml to a total volume of 70 ml) and left to react for 5 min at
room temperature. The reactions were stopped by the addition of
1:4 volumes of stop solution (1.5 M sodium acetate, pH 7, 1 M b-
mercaptoethanol and 1 mg/ml tRNA). DNA was precipitated with 4
volumes of ethanol and resuspended in piperidine 1 M. After
cleavage at 90uC for 30 min, reactions were stopped with chilling in
ice followed by precipitation with 0.3 M sodium acetate, pH 5.2
and 3 volumes of ethanol. The DNA samples were resuspended in
90% formamide and 50 mM EDTA, denatured at 90uC and run
for 2 h on a denaturing 20% polyacrylamide gel, prepared in TBE
and 8 M urea, pre-equilibrated at 55uC in a Sequi-Gen GT Nucleic
Acids Electrophoresis Apparatus (Bio-Rad, CA), which was
equipped with a thermocouple that allows a precise temperature
control. After running, the gel was fixed in a solution containing
10% acetic acid and 10% methanol, dried at 80uC and exposed to
Hyperfilm MP (GE Healthcare) for autoradiography.
Cell culture and proliferation assay
HeLa and T24 urinary bladder cancer cells were maintained in
exponential growth in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 20 mM L-glutamine and 10% foetal bovine serum
(Euroclone, Milan, Italy). For proliferative assays T24 cells were
seeded (1250 cells/well) the day before decoy treatment in a 96-
well plate. The G4-decoys, mixed to jetPEI (Polyplus transfec-
tion), were delivered to the cells at increasing concentrations up
to 800 nM. 48 h after the first delivery a second dose of
oligonucleotides was given to the cells. 72 h after the second
delivery, the cell viability was measured by resazurin assays
following standard procedures.
Dual luciferase assays
Firefly luciferase activity in cell lysates was measured and
normalized for Renilla luciferase activity using the Dual-Glo
Luciferase Assay System (Promega) following vendor’s instruc-
tions. Transfection was performed by mixing each vector 250 ng/
well with control plasmid pRL-CMV expressing Renilla luciferase
under control of CMV promoter 10 ng/well using Metafectene
transfection reagent (Biontex Laboratories, GmbH) following
manufacturer instruction. For cotransfection with pMAZ and/or
pSp1 100 ng of pHRAS-luc or mutant, with 10 ng of pRL-CMV,
were transfected with either 100 ng of pMAZ/pSp1 or pcDNA3
plasmid (empty vector) as mass for control transfections. Each
transfection was performed in triplicate. Luciferase assays were
performed 48 h after transfection following instructions. Samples
were read with Turner Luminometer and expressed as Relative
luminescence (see figure captions).
Recombinant MAZ and Sp1: purification and EMSA
Recombinant MAZ and Sp1 tagged to GST were expressed in
Escherichia coli BL21 DE3 plys using plasmid pGEX-MAZ and
Table 1. RT-PCR primers.
Oligonucleotides 59-39 sequence T, 6C
hHRAS for GGG GCA GTC GCG CCT GTG AA 60
hHRAS rev CCG GCG CCC ACC ACC ACC AG 60
hGAPDHfor CCC TTC ATT GAC CTC AAC TAC ATG 60
hGAPDHrev TGG GAT TTC CAT TGA TGA CAA GC 60
hHPRTfor AGA CTT TGC TTT CCT TGG TCA GG 60
hHPRTrev GTC TGG CTT ATA TCC AAC ACT TCG 60
hb2mglobulinrev CAT TCC TGA AGC TGA CAG CAT TC 60
hb2mglobulinfor TGC TGG ATG ACG TGA GTA AAC C 60
hmazfor CTC CAG TCC CGC TTC T 55
hmazrev GGG AGC AAG TCC ACC T 55
hSp1for CCC TTG AGC TTG TCC CT 50
hSp1rev CCT GTG AAA AGG CAC CA 50
doi:10.1371/journal.pone.0024421.t001
Table 2. G4-decoys used for HRAS gene.
Oligonucleotides 59-39 sequence
hras-2 biotin B-CGAGGCCGGGGCGGGGCGGGGGCGGGGGCGCGCGGT
hras-1 biotin B-CGGCTCGGGTTGCGGGCGCAGGGCACGGGCGGC
hras-1 (H1) TCGGGTTGCGGGCGCAGGGCACGGGCG
hras-2 (H2) CGAGGCCGGGGCGGGGCGGGGGCGGGGGCGCGCGGT
3 TCPGGGTTGCGGGCGCAGGGCA CGGGCGG
3-F F- TCPGGGTTGCGGGCGCAGGGCA CGGGCGG
4 TCPGGGTTGCGGGCGCAGGGPCA CGGGCGG
5 TCPGGGTTGCGGGCGCAGGGPCA CGGGCGG
6 CGPGGGCGGGGCGGGGGCGGGGGCG
7 CGPGGGCGGGGCGGGGGCGGGGGCG
8 CGPGGGCGGGPGCGGGGGCGGGGGCG
1450 GCGGTGTCGCPAAGACGCAAGACGCGGAGGCAG
B=biotin; P = TINA (S4); Underlined bases indicate LNA residue.
doi:10.1371/journal.pone.0024421.t002
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pGEX-Sp1. The bacteria were grown for 1–2 h at 37uC to an
optical density at 600 nm between 0.5–2.0 prior to induction with
IPTG (0.2 mM final concentration). Cells were allowed to grow
overnight at 30uC before harvesting. The cells were centrifuged at
5000 rpm, 4uC, the supernatant removed and the cells washed
twice with PBS. The pellet was resuspended in a solution of PBS
with 1 mM PMSF, 1 mM DTT and Protease Inhibitor Cocktails
(only for GST-tagged proteins) (Sigma-Aldrich). The bacteria were
lysed by sonication and centrifuged for 30 min at 4uC, 16000 rpm.
Glutathione Sepharose 4B (GE Healthcare) (50% slurry in PBS)
was added to the supernatant from the previous step and
incubated for 30 min at 4uC while shaking. The mix was
centrifuged for 5 min at 500 g and the resin was washed 3 times
with PBS. Proteins were eluted from the resin with a buffer
composed by 50 mM Tris-HCl pH 8 and 10 mM reduced
glutathione.
Chromatin immunoprecipitation
HeLa cells were plated in 2615 cm diameter plates, grown to
80% confluency (about 1.56107 cells) and fixed in formaldehyde
1% in PBS for 2 or 5 minutes. Chromatin immunoprecipitation
assays were performed using the ChIP-ITTM Express kit (Active
Motif, Rixensart, Belgium), as previously reported [24]. The
antibodies used are MAZ H-50 (sc-28745, Santa Cruz, Biotech-
nology, Inc), Sp1 (PEP 2) (sc-59, Santa Cruz, Biotechnology, Inc)
used at 20 ng/ml. The primers used are: (i) for control reaction,
specific for GAPDH (provided by the kit) that give a 160 bp
product; (ii) 59-GGCTCCTGACAGACGGG (hras-1for) and 59-
GCATGGGCTCCGTCC (hras-1rev) giving a 190 bp product;
(iii) 59-GGACGGAGCCCATGC (hras-2for) and 59-
CGTATTGCTGCCGCCT (hras-2rev) giving a 161 bp product.
Amplification products were separated by a 10% acrylamide gel in
TBE and visualized with a Gel–DOC apparatus (Bio-Rad
Laboratories, CA, USA).
shRNA transfections, RNA extraction and real-time PCR
Cells were seeded 200–400000/well in a 24 well plate. shRNA
plasmids were transfected the day after plating 0.5 mg/well.
Plasmids used are shRNA-control, shRNA-MAZ and shRNA-Sp1
(Santa Cruz Biotechnology, CA, USA). Cells were collected 48
and 72 h after transfection.
RNA extraction: RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA). cDNA synthesis: 5 ml of RNA in
DEPC-water was heated at 55uC and placed in ice. The solution
was added with 7.5 ml of a mix containing (final concentrations)
16buffer; 0.01 M DTT (Invitrogen); 1.6 mM primer dT [MWG
Biotech, Ebersberg, Germany; d(T)16]; and 1.6 mM random
primers (Promega); 0.4 mM dNTPs solution containing equi-
molar amounts of dATP, dCTP, dGTP and dTTP (Euroclone,
Pavia, Italy); 0.8 U/ml RNAse OUT; 8 U/ml of M-MLV reverse
transcriptase (Invitrogen). The reactions were incubated for 1 h
at 37uC and stopped with heating at 95uC for 5 min. As a
negative control the reverse transcription reaction was per-
formed with a sample containing DEPC water. Real-time PCR
reactions were performed with 16 iQTM SYBR Green Super-
mix (Bio-Rad Laboratories, CA, USA), 300 nM of each primer,
1 ml of RT reaction. The sequences of the primers used for
HRAS, GAPDH, b-2-microglobulin, Hypoxanthine Ribosyl
Transferase, MAZ and Sp1 amplifications are reported in
Table 1. The PCR cycle was: 3 min at 95uC, 40 cycles 10 s at
95uC, 30 s at 60uC with an iQ5 real-time PCR controlled by an
Optical System software version 2.0 (Bio-Rad Laboratories, CA,
USA).
Electrophoresis mobility-shift assays
Oligonucleotides were end-labelled with [c-33P]ATP and T4
polynucleotide kinase. Duplexes hras-1 and hras-2 were prepared
annealing (10 min at 95uC, overnight at room temperature) a
mixture containing 1:1,2 ratio of radiolabelled hras-1 or hras-2 with
the complementary strand in 50 mM Tris–HCl, pH 7.4, 100 mM
NaCl. Radiolabelled hras-1 and hras-2 were allowed to assume a
G4-DNA structure in 50 mM Tris–HCl, pH 7.4, 100 mM KCl,
by heating at 95uC and overnight incubation at 37uC. Before
EMSA, the radiolabelled oligonucleotides were treated for 30 min
at room temperature with different amounts of MAZ or Sp1 (or
extract), in 20 mM Tris–HCl, pH 8, 30 mM KCl, 1.5 mM
MgCl2, 1 mM DTT, 8% glycerol, 1% Phosphatase Inhibitor
Cocktail I (Sigma, Milan, Italy), 5 mM NaF, 1 mM Na3VO4,
2.5 ng/ml poly [dI-dC]. After incubation, the reaction mixtures
were loaded in 5% TBE (1X) polyacrylamide gel, thermostatted at
20uC. After running, the gel was dried and exposed to
autoradiography (GE Healthcare, Milan) for 24–36 h at 280uC.
FRET-melting experiments
FRET melting experiments were performed on a real-time PCR
apparatus (CFX 96, BioRad, Hercules, CA), using a 96-well plate
filled with 50 ml solutions of dual-labelled qhras-1 and qhras-2, in
50 mM Tris–HCl, pH 7.4, 50 mM KCl (qhras-1) or 100 mM
NaCl (qhras-2). The protocol, used for the melting experiments, is
the following: (i) equilibration step of 5 min at low temperature
(20uC); (ii) stepwise increase of the temperature of 1uC/min for 76
cycles to reach 95uC. All the samples in the wells were melted in
76 min.
Caspase assays
We performed Caspase activity assays using Apo-ONETM
Homogeneous Caspase-3/7 Assay (Promega), according to the
manufacturer’s protocol using a Microplate Spectrofluorometer
System (Molecular Devices, Concorde, Canada).
Supporting Information
Figure S1 Polymerase stop assays with a wild-type DNA
template containing hras-1 or hras-2 and a mutant template in
which four GRT point mutations were introduced in sequence
hras-2 to abrogate quadruplex formation. Taq polymerase is
arrested at the 39 end of hras-2, before the first run of guanines, in
keeping with the formation of a quadruplex structure by hras-2
(experimental conditions: 37uC, 140 mM KCl, 50 mM Tris-HCl
pH 7.4) When the DNA template is incubated with G4-DNA
ligands that stabilize quadruplex DNA, Taq polymerase is
completely arrested and only the truncated product is produced.
This is observed with porphyrin TMPyP4 and guanidine
phthalocyanines DIGP and Zn-DIGP at r = 4 (r = [ligand]/
[template]). Instead, TMPyP2, which does not bind to G4-DNA
does not affect the processivity of Taq polymerase. When the
experiment is performed with the mutated template, Taq
polymerase does not stop at the G-element and full product is
observed. A longer truncated product is observed with the mutated
template, probably due to a hairpin structure stabilized by CG and
GT base pairs. Polymerase stop assays with a DNA template
containing hras-1show that Taq polymerase is arrested in the
presence of phthalocyanines, indicating that the G-quadruplex
formed by hras-1 is less stable than that formed by hras-2.
(TIF)
Figure S2 CD spectra of the hras-1 and hras-2 mutants. CD
spectra in 50 mM Tris-HCl pH 7.4, 100 mM KCl of hras-1, hras-1
G4-DNA in HRAS Promoter and Decoy Oligonucleotides
PLoS ONE | www.plosone.org 13 September 2011 | Volume 6 | Issue 9 | e24421
mut (59-TCGGGTTGCGGGCGCAGGGCACCTGCG), hras-2
and hras-2 mut (59-CGAGGCCGGTGCGGTGCGGGGGC-
GGGGGCGCGCGGT). Cuvette 0.5 cm, DNA concentration
6 mM.
(TIF)
Figure S3 EMSA showing the binding between recombinant
MAZ-GST and Sp1-GST with duplexes hras-1 and hras-2. (a)
radiolabelled hras-1 duplex, 15 nM incubated for 30 min with 0,
0.5, 1, 1.5, 2 and 2.5 mg MAZ-GST; (b) radiolabelled hras-2
duplex, 15 nM incubated for 30 min with 0, 0.5, 1, 1.5, 2 and
2.5 mg MAZ-GST; (c) radiolabelled hras-2 duplex, 15 nM
incubated for 30 min with 0, 0.5, 1 and 2.5 mg Sp1-GST.
(TIF)
Figure S4 SDS-PAGE of eluate from Glutathione Sepharose 4B
column loaded with protein extract of BL21 bacteria transformed
with a plasmid encoding for MAZ-GST or Sp1-GST (a) lane 1:
bacterial extract; lane 2: proteins that did not bind the resin (flow
through); lane 3, fraction eluted with 10 mM glutathione; (b) lane
1: molecular weights; lane 2: bacterial extract; lane 3: proteins that
did not bind the resin (flow through); lane 4, column wash; lane 5:
1st elution with 10 mM glutathione; lane 6: 2nd elution with
10 mM glutathione.
(TIF)
Figure S5 Silencing in HeLa cells of MAZ and Sp1 by
commercial shRNAs. HeLa cells have been treated with MAZ
shRNA or Sp1 shRNA complexed with Metafectene. As control
we treated HeLa cells with control shRNA. MAZ and Sp1 specific
shRNA and control shRNA have been purchased from Santa
Cruz Biotechnology (USA). After 48 h, total RNA was extracted,
transformed in cDNA and used for real-time experiments. The
levels of MAZ and Sp1 transcripts have been measured and
reported in graph relatively to the expression of three housekeep-
ing genes: GAPDH, b2- microglobulin, hypoxanthine ribosyl
transferase.
(TIF)
Figure S6 (a) SDS-PAGE of fractions eluted from a Glutathione
Sepharose 4B column loaded with protein extract obtained from
non-transformed BL21 DE3 plysS bacteria (lanes 5 and 6).
Fractions eluted with 10 mM reduced glutathione do not contain
bacterial proteins bound non-specifically to the resin; (b) (top)
FRET melting of 200 nM quadruplex hras-1 in 50 mM Tris-HCl,
pH 7.4, 50 mM KCl, 50 mM Zn-acetate in the presence of FPLC
purified GST at DNA:protein ratios of 1:0, 1:1 and 1:5; (bottom)
FRET melting of 200 nM quadruplex hras-2 in 50 mM Tris-HCl,
pH 7.4, 100 mM NaCl, 50 mM Zn-acetate in the presence of
FPLC purified GST at DNA:protein ratios of 1:0, 1:1 and 1:5.
(TIF)
Figure S7 (Top) putative structures of the designed G4-decoys.
The yellow rectangles represent the TINA unit (P); (bottom)
Structure of the TINA unit covalently inserted in the decoy
oligonucleotides.
(TIF)
Figure S8 Proliferation assay with T24 cells untreated and
treated with 800 nM G4-decoys 3,4,5 (mimicking qhras-1) and G4-
decoys 6,7,8 (mimicking qhras-2). Decoy 637 is a random sequence
containing one P unit. Two doses, one 48 h after the other, of
800 nM G4-decoys mixed with polyethylenimine have been
delivered to T24 cells. Viable cells, measured by a resazurin
assay, have been performed at increasing times from 1st treatment.
(TIF)
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